No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
www.wuxibiologics.comNo one on the platform currently holds 2269.HK.
No tracked institution reports a position in 2269.HK as of their last filing.
No one on the platform has traded 2269.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 12.3% | 10.9% | 11.4% | — | — | — |
| Rev. Growth % | 16.7% | 31.2% | ||||
| Profit Margin % | 22.5% | 24.5% | 23.3% | |||
| Free Cash Flow Margin % | 12.8% | -2.0% | -23.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Also held through funds
2 more books hold 2269.HK indirectly · FLCH 0.8% of fund
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $26.9B | +24.3% | $1.48 | $1.24–$1.72 | — | 16 |
| 2027 | $32.4B | +20.2% | $1.85 | $1.47–$2.17 | — | 17 |
| 2028 | $38.9B | +20.0% | $2.27 | $1.83–$2.61 | — | 16 |
| 2029 | $42.8B | +10.2% | $2.71 | $2.51–$2.99 | — | 13 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-25 | $0.52 | $0.67 | +28.9% |
| 2026-03-24 | $0.70 | $0.68 | -3.7% |
| 2025-08-19 | $0.49 | $0.60 | +22.2% |
| 2025-03-24 | $0.47 | $0.24 | -48.9% |
| 2024-08-21 | $0.44 | $0.38 | -14.6% |
| 2024-03-27 | $0.28 | $0.29 | +4.9% |
| 2023-08-23 | $0.59 | $0.56 | -5.1% |
| 2023-03-23 | $0.43 |
| $0.49 |
| +14.3% |
| +3.08% |
| $29.3B |
| — |
| 2268.HKWuXi XDC Cayman Inc | $74.50 | -1.72% | $94.3B | — |
| 2696.HKShanghai Henlius Biotech, Inc. | $64.55 | +0.00% | $35.1B | — |
Source: Financial Modeling Prep · peers by sector/industry